Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.